tnbc treatment: platinum-based therapy and parp inhibition
Published 4 years ago • 149 plays • Length 0:58Download video MP4
Download video MP3
Similar videos
-
4:35
role of neoadjuvant platinum-based therapy for tnbc
-
1:22
dora: durvalumab and olaparib in platinum treated advanced tnbc
-
6:08
role of parp inhibition and i/o therapy in tnbc
-
1:16
dr. tolaney on platinum-based therapy in neoadjuvant setting of tnbc
-
2:05
treatment advances in tnbc
-
1:51
optimal chemotherapy combinations in tnbc gbrca subtypes
-
5:19
parp inhibitors for brca-associated tnbc
-
5:53
combining parp inhibitors checkpoint inhibitors in tnbc
-
6:10
role of parp inhibition and i/o therapy in tnbc
-
5:53
treating early-stage tnbc
-
7:23
combining parp and checkpoint inhibitors in tnbc
-
2:38
olaparib durvalumab as a chemotherapy-free maintenance strategy in platinum treated advanced tnbc
-
8:50
case 4: chemotherapy or parp inhibitors for brca tnbc
-
8:08
parp inhibitors and carboplatin for neoadjuvant triple negative breast cancer treatment
-
1:30
emerging immunotherapy beyond checkpoint inhibitors for tnbc
-
5:21
optimal neoadjuvant and adjuvant therapy for patients with early tnbc
-
5:18
parp inhibitors for brca-mutated tnbc
-
3:46
case 4: parp inhibitors for treating brca triple-negative breast cancer
-
1:39:18
expanding the benefits of checkpoint inhibitors and targeted agents in triple-negative breast cancer